Skip to Content

Obesity Is Not a Willpower Problem. It's a Medical One.

Your body has been working against you. Now, medicine can work with you.

If you've tried diets, cut portions, pushed through workouts — and still struggled — you weren't failing. Your biology was. Obesity is a chronic, progressive medical condition driven by hormones, brain chemistry, and metabolic adaptation. It is not a character flaw. And it deserves the same clinical rigour we give to diabetes or hypertension.

The Disease Model

Your Brain Is Defending Your Weight. That's Not a Metaphor.

Once obesity is established, the body adapts to protect it. Hunger signals increase. Energy expenditure drops. Weight regain is actively promoted at a biological level. This is why willpower alone has a near-zero success rate long-term — not because people aren't trying hard enough, but because the system is working against them.

Modern medicine is unambiguous: obesity is a chronic, relapsing metabolic disease. The 2025 Indian Obesity Commission recognises this, and so does Leanova. Treating it requires medical tools — not motivation posters.

"I wish everyone understood it's so much more than eat less and move more."

— A person living with obesity

Indian-Specific Thresholds

The Standard BMI Chart Wasn't Built for You.

Global BMI thresholds were developed largely on Western population data. South Asians develop insulin resistance, visceral fat accumulation, and cardiovascular risk at significantly lower BMI values. That's why Leanova — and the 2025 Indian Obesity Commission guidelines — applies different clinical thresholds.

BMI Range Classification What It Means for You
18.5 – 22.99 Normal Optimal metabolic health
23.0 – 24.9 Obesity Grade I Elevated metabolic risk — lifestyle intervention indicated
25.0 – 27.5 Obesity Grade II Pharmacotherapy may be appropriate
27.6 – 32.4 Obesity Grade III Pharmacotherapy strongly indicated
≥ 32.5 Obesity Grade IV Intensive medical management required

Global guidelines begin "obesity" at BMI ≥30. Indian guidelines recognise that metabolic complications begin earlier — and treatment should too.

Mind & Metabolism

Obesity Doesn't Just Live in the Body.

People with obesity are significantly more likely to experience depression, anxiety, disordered eating, and low self-worth. This isn't coincidence — it's biology and stigma operating together.

Chronic systemic inflammation impairs neurotransmitter signalling. Elevated cortisol drives visceral fat accumulation and increases appetite. Weight-based discrimination activates shame, reduces care-seeking, and deepens isolation. And certain psychiatric medications compound the problem by promoting weight gain.

The relationship runs in both directions: obesity worsens mental health, and poor mental health worsens obesity. Any treatment that ignores this cycle will fail.

The Cycle

Poor mental health → emotional eating → weight gain → stigma & shame → worsened mental health.

Breaking this cycle requires medical and psychological support — together, not as an afterthought.

Condition How Obesity Contributes How It Worsens Obesity
Depression Inflammation, hormonal dysregulation, social stigma Reduces motivation; emotional eating
Anxiety Body image distress, anticipatory shame Avoidance of activity; stress eating
Low Self-Esteem Weight-based discrimination Reduced confidence in behaviour change
Disordered Eating Psychological distress triggers binge patterns Perpetuates weight gain cycle

This is why psychological support at Leanova is not optional. It is built into the programme. Treating only one dimension of a multi-dimensional disease yields limited, unsustained results.

Clinical Benefits

Even 5% Makes a Measurable Difference.

Weight loss does not need to be dramatic to be meaningful. Evidence-based medicine is clear: improvements in metabolic health, quality of life, and physical function begin at just 5% body weight reduction — and scale progressively from there.

≤ 5% weight loss

Improved blood pressure. Better blood glucose and HbA1c control.

5 – 10% weight loss

Type 2 diabetes prevention. Improved lipid profile. Liver fat reduction (MASLD). Better PCOS outcomes. Measurable improvements in self-esteem, mood, and physical function.

10 – 15% weight loss

Reduced cardiovascular events. Improved knee osteoarthritis. Regression of liver disease (MASH).

> 15% weight loss

Type 2 diabetes remission. Reduced heart failure risk. Lower cardiovascular mortality.

Quality-of-life improvements increase with greater weight loss — and are maintained over time, even if small weight regain occurs. The goal is not perfection. Meaningful, sustained improvement is clinically significant.

Individual results vary. Medical assessment is required.

Pharmacotherapy

This Is How the Medicine Works.

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones released by the gut after eating. They regulate hunger, satiety, insulin secretion, and fat metabolism — the same systems hijacked by obesity. Incretin-based medications restore balance to these pathways, working with your biology rather than against it.

🧠 Brain

Activates hypothalamic satiety centres. Reduces hunger signals and food cravings.

🫀 Stomach

Delays gastric emptying. Sustains fullness after meals.

🫘 Pancreas

Stimulates insulin release in a glucose-dependent manner. Very low hypoglycaemia risk.

🧬 Fat Tissue

Improves insulin sensitivity. Reduces fat cell formation.

🫁 Liver

Reduces glucose production. Promotes fat metabolism.

Multi-System Protection

The Benefits Go Far Beyond Weight.

Incretin-based therapies represent a paradigm shift in obesity medicine. Clinical trials have demonstrated meaningful protection across multiple organ systems — independent of weight loss itself.

Heart Health

Significant reduction in major adverse cardiovascular events — heart attack, stroke, and cardiovascular death. Improved blood pressure, LDL cholesterol, and systemic inflammation.

Kidney Protection

GLP-1 therapies slow eGFR decline and reduce albuminuria. Clinical trials show they can delay or prevent kidney failure, dialysis, or transplant need — independent of glycaemic control.

Liver Health

Regression of liver fat (steatosis) and prevention of liver scarring (fibrosis) in MASLD and MASH — conditions disproportionately prevalent among Indians.

Metabolic Control

Highly effective reduction in blood glucose and HbA1c with low hypoglycaemia risk. Demonstrated ability to prevent progression from prediabetes to type 2 diabetes.

Sleep Apnoea

Significant reduction in apnoea and hypopnoea events. Some patients no longer require CPAP after treatment.

Emerging Research

Early evidence suggests potential benefits in Parkinson's disease motor decline, all-cause dementia incidence, and substance use disorders — through central reward pathway modulation.

Our Approach

Four Pillars. One Continuous Treatment.

Effective obesity care is not a single intervention. It is a sustained, multi-dimensional treatment plan. International guidelines — AHA, ESC, and the Indian Obesity Commission — are unequivocal: obesity requires medical, nutritional, behavioural, and long-term maintenance support working in parallel.

01

Lifestyle Intervention

Calorie-appropriate nutrition with adequate protein. Resistance training and physical activity. Sleep optimisation. Stress management. Behavioural change strategies grounded in science — not willpower.

02

Pharmacotherapy (when indicated)

GLP-1 receptor agonists and GIP/GLP-1 dual agonists (tirzepatide) — prescribed only when clinically eligible, titrated carefully, monitored continuously. Medicine is a tool, not a shortcut.

03

Metabolic Optimisation

Insulin resistance management. Sleep apnoea treatment. PCOS support. Fatty liver disease. Dyslipidaemia. Micronutrient correction. Treating the whole metabolic picture, not just the number on the scale.

04

Long-Term Maintenance

Ongoing clinical follow-up. Relapse prevention. Habit reinforcement. Muscle preservation. Mental health monitoring. Because obesity is a chronic condition — and chronic conditions require continuous care.

Evidence-Based

What the Evidence Actually Says.

These are not opinions. They are the clinical positions of global and Indian medical bodies — summarised plainly.

1.

Obesity is a chronic medical disease, not a lifestyle choice.

2.

It is caused by biology — hormones, brain regulation, metabolism, and genetics. Not a failure of discipline.

3.

Weight stigma and blame actively harm health outcomes — reducing care-seeking and worsening long-term results.

4.

Even 5% weight loss produces measurable improvements in physical function, mood, self-esteem, and quality of life.

5.

These improvements scale with greater weight loss — and are maintained over time, even with minor regain.

6.

Once obesity is established, the body biologically resists weight loss. If a diet failed you, biology won — not you.

7.

Psychological support is not optional in obesity care. Clinical guidelines require it as a standard component of treatment.

8.

Success is measured by improved health, function, and quality of life — not exclusively by kilograms lost.

9.

Building self-efficacy and intrinsic motivation leads to better adherence and more sustainable results than external pressure.

10.

Obesity requires long-term, continuous care. Short-term or one-time interventions are insufficient for a chronic disease.

Your body deserves medical care.
Your mind deserves compassion.

Leanova is a doctor-led metabolic treatment programme built for Indian adults — combining GLP-1 pharmacotherapy, culturally matched nutrition, and behavioural coaching. This is not a challenge. It's a treatment.

For educational purposes only. Treatment is prescribed by licensed medical professionals. All medications are prescribed under direct physician supervision following clinical eligibility criteria. Individual results vary.